E-viri
Recenzirano
Odprti dostop
-
Kelley, Robin Kate; Miksad, Rebecca; Cicin, Irfan; Chen, YenHsun; Klümpen, Heinz-Josef; Kim, Stefano; Lin, Zhong-Zhe; Youkstetter, Jillian; Hazra, Saswati; Sen, Suvajit; Cheng, Ann-Lii; El-Khoueiry, Anthony B; Meyer, Tim; Abou-Alfa, Ghassan K
British journal of cancer, 03/2022, Letnik: 126, Številka: 4Journal Article
Albumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received prior sorafenib based on the phase 3 CELESTIAL trial (NCT01908426). Cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated HCC. Patients were randomised 2:1 to receive cabozantinib 60 mg or placebo orally every day. Clinical outcomes in patients with ALBI grade 1 or 2 at baseline were evaluated in CELESTIAL. ALBI scores were retrospectively calculated based on baseline serum albumin and total bilirubin, with an ALBI grade of 1 defined as ≤ -2.60 score and a grade of 2 as a score of > -2.60 to ≤ -1.39. Cabozantinib improved OS and PFS versus placebo in both ALBI grade 1 (hazard ratio HR 95% CI: 0.63 0.46-0.86 and 0.42 0.32-0.56) and ALBI grade 2 (HR 95% CI: 0.84 0.66-1.06 and 0.46 0.37-0.58) subgroups. Adverse events were consistent with those in the overall population. Rates of grade 3/4 adverse events associated with hepatic decompensation were generally low and were more common among patients in the ALBI grade 2 subgroup. These results provide initial support of cabozantinib in patients with advanced HCC irrespective of ALBI grade 1 or 2. ClinicalTrials.gov number, NCT01908426.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.